All In MedTech

FDA Clearance Tracker · P990081-S060

PATHWAY anti-HER-2/neu (4B5) Rabbit Monoclonal Primary Antibody

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Aug 25, 2026 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Aug 25, 2026

Approved

Time to decision

153 days

Received Mar 25, 2026. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Panel Track

Device class

Class III

The decision

FDA number
P990081-S060
Device name
PATHWAY anti-HER-2/neu (4B5) Rabbit Monoclonal Primary Antibody
Applicant location
Tucson, AZ
Received
Mar 25, 2026
Decided
Aug 25, 2026
Decision
Approved
Supplement type
Panel Track
Reason for supplement
Labeling Change - Indications/instructions/shelf life/tradename
Original approval
P990081

Device type

Device class
Class III

Every decision under product code MVC

FDA's approval statement

As written in FDA's record.

Approval for the PATHWAY anti-HER-2/neu (4B5) Rabbit Monoclonal Primary Antibody as a companion diagnostic (CDx) for identifying patients with gastroesophageal adenocarcinoma (gastric, gastroesophageal junction, and esophageal adenocarcinoma) who may be eligible for treatment with ZIIHERA (zanidatamab).

Source documents

Other decisions for Ventana Medical Systems, Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

7 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.